SEPN

Septerna, Inc. (SEPN) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) therapies using its proprietary Native Complex Platform. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Liquidity: As of September 30, 2025, the company held $561.6 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations through at least 2029.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased significantly to $21.5 million in Q3 2025 from $0.2 million in Q3 2024. This is primarily driven by the recognition of revenue from the Novo Nordisk Collaboration Agreement, which became effective in July 2025 with a $195.0 million upfront payment.
• Net Income Turnaround: The company reported a net income of $8.2 million for Q3 2025, compared to a net loss of $20.5 million in Q3 2024. This shift was driven by the revenue increase and a $12.5 million gain on the sale of a non-financial asset (a milestone payment from Vertex Pharmaceuticals).
• Operating Expenses: Total operating expenses decreased in Q3 2025 compared to Q3 2024 due to the $12.5 million gain offsetting higher R&D and G&A costs. However, on a year-to-date basis, operating expenses increased by $17.1 million due to expanded clinical and preclinical activities.
• Balance Sheet: Total assets grew by $150.1 million year-over-year, largely due to the accumulation of cash and deferred revenue from the Novo Nordisk deal.

Guidance, Outlook, and Risks

• Pipeline Updates:
  • SEP-479 (PTH1R Agonist): Selected as the new development candidate for hypoparathyroidism after discontinuing SEP-786 due to hyperbilirubinemia. Phase 1 trial initiation is planned for the first half of 2026.
  • SEP-631 (MRGPRX2 NAM): First participants dosed in Phase 1 clinical trial for chronic spontaneous urticaria in August 2025. Initial data expected in H1 2026.
  • TSHR NAM Program: Advancing lead compounds for Graves' disease and thyroid eye disease.
• Collaborations: The Novo Nordisk agreement includes potential milestone payments of up to $498.0 million per R&D program and tiered royalties. The Vertex agreement concluded with the $12.5 million milestone payment.
• Risks:
  • Regulatory Disruptions: Significant risk factors include potential U.S. federal government shutdowns and staffing reductions at the FDA, which could delay IND reviews and approvals.
  • Macroeconomic Factors: Exposure to tariffs on pharmaceutical imports and raw materials, as well as general market volatility.
  • Development Risk: As a clinical-stage company, Septerna has no approved products and relies on successful clinical trials and future financing.

Investor Verification Checklist

• Revenue Recognition: Verify the amortization schedule and performance obligations associated with the $195.0 million Novo Nordisk upfront payment to understand future revenue visibility.
• One-Time Gains: Confirm that the $12.5 million gain from Vertex is non-recurring and does not reflect core operational profitability.
• Cash Burn Rate: Assess the sustainability of the $561.6 million cash position against the projected increase in R&D spending for the SEP-479 and SEP-631 clinical trials.
• Regulatory Timeline: Monitor the impact of FDA staffing levels and potential government shutdowns on the planned H1 2026 Phase 1 initiation for SEP-479.
• Stock-Based Compensation: Review the $25.1 million in unrecognized stock-based compensation expense, which will impact future operating margins.